Hong Kong SAR | Germantown, MD, USA | Suzhou Biobay, China, Oct 6, 2023 - Sirnaomics Ltd. (the “Company”; stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company engaging in the discovery and development of advanced RNAi therapeutics, today hereby announce that Dr. Dai Xiaochang, Executive Director and Chief Strategy Officer of Sirnaomics, represented the Group at the launch ceremony to sign a Strategic Enterprise Partnership Agreement with OASES . Witnessed by Chief Executive John Lee and Financial Secretary Paul Chan, Sirnaomics and the Hong Kong Special Administrative Region Government (“The Government”) will jointly promote the development of Hong Kong's innovation and technology (I&T) ecosystem. Sirnaomics’ subsidiary RNAimmune and strategic partner EDIRNA, were also invited to attend the launch ceremony to become the first batch of strategic enterprise partners.

Dr. Dai Xiaochang, Executive Director, and Chief Strategy Officer of Sirnaomics, said, “As an international financial center and an important hub of knowledge-based economy, Hong Kong provides an excellent business environment and a rich professional talent base. As the first RNA therapeutics pharmaceutical company to enter late-stage research and development in oncology field, the Group hopes to contribute to the development of Hong Kong's innovation and technology by becoming a key corporate partner in Hong Kong, and to enhance further international influence of nucleic acid drug innovation and industrialization in Hong Kong and the Greater Bay Area.”

Dr. Patrick Lu, Founder, Executive Director, and CEO of Sirnaomics, said, “ We are pleased and honored to be recognized by the Government and OASES as a Strategic Enterprise. As a leading biopharmaceutical company in RNA therapeutics, we are committed to driving innovation in the industry and introducing new therapies to the market. We have established an R&D Center in Hong Kong to consolidate the Group's strengths which will be a strong asset in helping Hong Kong become Asia's leading RNA Medicine Port.”

During the media interview, Mr. Nigel Yip, Chief Financial Officer of Sirnaomics said, " Sirnaomics with our subsidiary RNAimmune and strategic partner EDIRNA, have all officially moved into Hong Kong Science Park. The Group will take this opportunity to continue extending and strengthening our development strategy in the Asia-Pacific region and to further improve the Group's business market plan. We are confident to believe the future of scientific research and development will flourish in Hong Kong with the full Government support."

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 and STP707. STP122G represents the first drug candidate of GalAhead™ technology entering clinical development. With establishment of the Group’s manufacturing facility, Sirnaomics currently is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.

About RNAimmune

RNAimmune is an international biopharmaceutical company focusing on mRNA vaccine and therapeutics development. Its global headquarter is in Germantown, Maryland, USA, while the China headquarter is located in International BioIsland, Guangzhou. RNAimmune has received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. In addition, RNAimmune has various independent proprietary R&D platforms, including artificial-intelligence and directed neoantigen prediction, ALEPVA algorithm for nucleic acid sequence design and lipid nanoparticle (LNP) carrier systems. RNAimmune also deployed various vaccines and therapeutics pipelines, including vaccines for infectious diseases (COVID-19, influenza, VZV and RSV etc.) and cancer vaccines (RAS, NY-ESO-1), and protein replacement medication. RNAimmune has extremely high potential and has become one of the leading companies in the field of mRNA vaccines and therapeutics. Learn more at: www.rnaimmune.com.

About EDIRNA

EDIRNA is a privately held and innovative biotech company focused on RNA-Editing technology for discovery and development of novel therapeutics. The company’s mission: to discover and develop novel RNA medicine using innovative RNA-Editing technology with a global outreach. The company’s Edit-to-Cure Therapeutics™ platform uses RNA-editing technologies to address the root cause of disease progression. Learn more at: www.EDIRNA.us.